The Effect of Vitamin D3 and Ketoconazole Combination on VDR-mediated P-gp Expression and Function in Human Colon Adenocarcinoma Cells: Implications in Drug Disposition and Resistance

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 2, 2011, Pages 97-102

  Kota, Bhavani P ^a   Allen, John D ^b   Roufogalis, Basil D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CENTENARY INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLCHICINE; GLYCOPROTEIN P; KETOCONAZOLE; VITAMIN D RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL PROTECTION; CELL VIABILITY; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION;

ADENOCARCINOMA; CALCITRIOL; CELL LINE, TUMOR; COLCHICINE; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; KETOCONAZOLE; P-GLYCOPROTEIN; RECEPTORS, CALCITRIOL; RHODAMINE 123;

EID: 79960273056     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00693.x     Document Type: Article

References (43)

1. Verstuyf A, Segaert S, Verlinden L, Bouillon R, Mathieu C. Recent developments in the use of vitamin D analogues. Expert Opin Investig Drugs 2000;9:443-55.
2. Haussler MR, Norman AW. Chromosomal receptor for a vitamin D metabolite. Proc Natl Acad Sci U S A 1969;62:155-62.
3. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the dunning rat prostate model system. Urology 1997;50:999-1006.
4. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1, 25-Dihydroxycholecalciferol (1, 25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-9.
5. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
6. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dial 2005;18:276-89.
7. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990;19:559-63.
8. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063-9.
9. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500-3.
10. Knekt P, Laaksonen M, Mattila C, Härkänen T, Marniemi J, Heliövaara M et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008;19:666-71.
11. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8.
12. Brown SE. Vitamin D and fracture reduction: an evaluation of the existing research. Altern Med Rev 2008;13:21-33.
13. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7:1043-51.
14. Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ et al. Cisplatin potentiates 1, 25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 2002;1:821-9.
15. 3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 1991;51:2848-53.
16. Peehl DM, Seto E, Feldman D. Rationale for combination ketoconazole/vitamin D treatment of prostate cancer. Urology 2001;58:123-6.
17. Pols HA, Birkenhäger JC, Schilte JP, Visser TJ. Evidence that the self-induced metabolism of 1, 25-dihydroxyvitamin D-3 limits the homologous up-regulation of its receptor in rat osteosarcoma cells. Biochim Biophys Acta 1988;970:122-9.
18. Reinhardt TA, Horst RL. Ketoconazole inhibits self-induced metabolism of 1, 25-dihydroxyvitamin D3 and amplifies 1, 25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells. Arch Biochem Biophys 1989;272:459-65.
19. Aboraia AS, Makowski B, Bahja A, Prosser D, Brancale A, Jones G et al. Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones. Eur J Med Chem 2010;45:4427-34.
20. Swami S, Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1, 25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005;241:49-61.
21. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Virtamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
22. Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 2010;39:401-18.
23. Ambudkar SV, Kim IW, Sauna ZE. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006;27:392-400.
24. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
25. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
26. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-87.
27. Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992;102:879-85.
28. Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 1999;16:225-31.
29. Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37:429-35.
30. Tachibana S, Yoshinari K, Chikada T, Toriyabe T, Nagata K, Yamazoe Y. Involvement of Vitamin D receptor in the intestinal induction of human ABCB1. Drug Metab Dispos 2009;37:1604-10.
31. Saeki M, Kurose K, Tohkin M, Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol 2008;76:531-42.
32. Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang KS. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha, 25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J Pharmacol Exp Ther 2009;330:389-402.
33. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha, 25-dihydroxy vitamin D3. Mol Pharmacol 2001;60:1399-406.
34. Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, Pang KS. 1alpha, 25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm Drug Dispos 2009;30:457-75.
35. Chow EC, Sun H, Khan AA, Groothuis GM, Pang KS. Effects of 1alpha, 25-dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and kidney in vivo. Biopharm Drug Dispos 2010;31:91-108.
36. Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and functions of P-glycoprotein. Curr Med Chem 2010;17:786-800.
37. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1by rifampin. J Biol Chem 2001;276:14581-7.
38. Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem 2005;386:503-13.
39. Efferth T, Löhrke H, Volm M. Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 1989;9:1633-7.
40. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
41. Engman HA, Lennernäs H, Taipalensuu J, Otter C, Leidvik B, Artursson P. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J Pharm Sci 2001;90:1736-51.
42. Aiba T, Susa M, Fukumori S, Hashimoto Y. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1alpha, 25-dihydroxyvitamin D(3) in human intestinal cell lines, Caco-2 and LS180. Drug Metab Pharmacokinet 2005;20:268-74.
43. Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010;151:4301-12.